SPARSENTAN ( DrugBank: Sparsentan )


3 diseases
IDDisease name (Link within this page)Number of trials
66IgA nephropathy18
218Alport syndrome6
222Primary nephrotic syndrome24

66. IgA nephropathy


Clinical trials : 275Drugs : 258 - (DrugBank : 82) / Drug target genes : 36 - Drug target pathways : 140 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

218. Alport syndrome


Clinical trials : 30Drugs : 36 - (DrugBank : 15) / Drug target genes : 8 - Drug target pathways : 46 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

222. Primary nephrotic syndrome


Clinical trials : 310Drugs : 295 - (DrugBank : 117) / Drug target genes : 63 - Drug target pathways : 194 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries